Research Analysts Issue Forecasts for NMRA Q3 Earnings

Key Points

• Analysts at HC Wainwright have raised their Q3 2025 earnings per share estimate for Neumora Therapeutics from ($0.46) to ($0.39).
• Neumora recently reported a quarterly EPS of ($0.33), exceeding analyst expectations by $0.05.
• Institutional investors hold approximately 47.65% of Neumora Therapeutics' stock, with notable increases in stakes from several hedge funds.

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Research analysts at HC Wainwright increased their Q3 2025 earnings estimates for shares of Neumora Therapeutics in a report released on Thursday, August 7th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their previous forecast of ($0.46). The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics' Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.54) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at ($1.67) EPS, FY2028 earnings at ($1.27) EPS and FY2029 earnings at ($0.09) EPS.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.05.

A number of other equities research analysts have also weighed in on NMRA. Needham & Company LLC reissued a "buy" rating and set a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday, May 13th. Mizuho boosted their target price on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $7.14.

Neumora Therapeutics Trading Down 2.2%

NMRA traded down $0.04 during trading on Monday, reaching $1.53. 230,868 shares of the company's stock were exchanged, compared to its average volume of 2,093,414. Neumora Therapeutics has a one year low of $0.61 and a one year high of $17.19. The company has a current ratio of 10.54, a quick ratio of 10.54 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $246.97 million, a PE ratio of -0.98 and a beta of 2.91. The firm has a fifty day moving average price of $1.28 and a two-hundred day moving average price of $1.18.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of NMRA. RBF Capital LLC bought a new stake in shares of Neumora Therapeutics in the 2nd quarter worth $117,000. Cerity Partners LLC grew its stake in shares of Neumora Therapeutics by 7.2% in the 2nd quarter. Cerity Partners LLC now owns 324,219 shares of the company's stock worth $238,000 after acquiring an additional 21,714 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Neumora Therapeutics by 10.4% in the 2nd quarter. Federated Hermes Inc. now owns 314,119 shares of the company's stock worth $230,000 after acquiring an additional 29,543 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Neumora Therapeutics in the 2nd quarter worth $183,000. Finally, Invesco Ltd. grew its stake in shares of Neumora Therapeutics by 6.8% in the 2nd quarter. Invesco Ltd. now owns 132,038 shares of the company's stock worth $97,000 after acquiring an additional 8,383 shares in the last quarter. Institutional investors and hedge funds own 47.65% of the company's stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.